3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Conditions
Thrombocythemia, Essential
2
Myeloproliferative Disorders
2
Polycythemia Vera
1
Interventions
peginterferon alfa-2a
2
liposomal amphotericin B
2
anagrelide
2
Hydroxyurea
2
Early Intervention, Educational
2
Aspirin
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
peginterferon alfa-2b
1
bomedemstat
1
Pharmacogenomic Testing
1
Ondansetron
1
N(4)-oleylcytosine arabinoside
1
Morphine
1
Ketamine
1
Hypericum extract LI 160
1
Fentanyl
1
Dextromethorphan
1
Dalteparin
1
Caspofungin
1
Asian ginseng
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Thrombocythemia, Essential
×
anagrelide
×
Clear all
NCT04285086
2025-08-13
SURPASS ET
PharmaEssentia
Phase 3
Active not recruiting
174 enrolled
NCT02076815
2015-07-29
TEAM-ET
AOP Orphan Pharmaceuticals AG
Phase 3
Completed
106 enrolled